Skip to contentpdufa.bio

MBX 4291 (GLP-1/GIP co-agonist prodrug)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

MBX 4291 (GLP-1/GIP co-agonist prodrug) is a MBX Biosciences, Inc. program in obesity. Its next catalyst is a Readout in Q4 2026.

MBX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: obesity. Sponsor: MBX Biosciences, Inc. (MBX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026MBX

Specialist biotech funds holding MBX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors3,074,853$180.2 millionfiled November 16, 2026
Cormorant Asset Management375,000$22.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is MBX 4291 (GLP-1/GIP co-agonist prodrug)'s next FDA decision or readout?

The next tracked catalyst for MBX 4291 (GLP-1/GIP co-agonist prodrug) is a Readout in Q4 2026.

What happened at MBX 4291 (GLP-1/GIP co-agonist prodrug)'s most recent FDA decision?

No FDA decision for MBX 4291 (GLP-1/GIP co-agonist prodrug) is in our archive yet.

What is MBX 4291 (GLP-1/GIP co-agonist prodrug) used for?

In our records MBX 4291 (GLP-1/GIP co-agonist prodrug) is under review or in development for obesity.

Who makes MBX 4291 (GLP-1/GIP co-agonist prodrug)?

MBX Biosciences, Inc. (MBX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.